Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS

Core Insights - Johnson & Johnson MedTech is presenting new clinical and real-world data from its VARIPULSE™ Platform for pulsed field ablation procedures at the APHRS and JHRS joint annual meeting in November 2025 [1][3][4] Group 1: Product and Platform Details - The VARIPULSE™ Platform includes the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 Mapping System, and is approved for use in multiple regions including the U.S., Europe, and Asia Pacific [2] - Over 25,000 procedures have been performed using the VARIPULSE™ Platform across various countries [2] Group 2: Clinical Evidence and Presentations - Key presentations at the conference will cover various studies, including the QUEST AF study on persistent atrial fibrillation ablation and the VARIPURE study on workflow efficiency in AF procedures [5] - Additional sessions will focus on the impact of age and diagnosis-to-ablation time on outcomes, as well as procedural characteristics related to same-day discharge after pulsed field ablation [5] Group 3: Commitment to Innovation - Johnson & Johnson MedTech emphasizes its commitment to advancing scientific knowledge and improving patient outcomes through collaborations and real-world evidence expansion [3][6] - The company aims to accelerate patient-centered innovation in atrial fibrillation care [6]